Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Matosinhos – page 5

691 clinical trials in Matosinhos, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Matosinhos at a glance
691
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

691 trials in Matosinhos

Open in trial search

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Phase 3 Study of Pridopidine Hydrochloride for Safety and Efficacy in Adults with Huntington’s Disease

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pridopidine hydrochloride
  • Sponsor:Ferrer Internacional S.A.

A Study of Baricitinib to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

A Study of Baricitinib to Delay Type 1 Diabetes in Children and Adults at Risk of Developing the Disease

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Baricitinib
  • Sponsor:Eli Lilly & Co.

HIV infection

Recruiting

Safety and efficacy of GS-3242 drug combination compared with standard drug combination in treatment‑naive adults with HIV‑1

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Gilead Sciences Inc.

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Phase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study of subcutaneous anifrolumab pharmacokinetics, pharmacodynamics and safety in children aged 5 to <18 years with systemic lupus erythematosus

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Belumosudil
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Sapablursen
  • Sponsor:Deciphera Pharmaceuticals Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Matosinhos

What the registry says about research in the country

01 Neurological Disorders

Innovative research focusing on Frontotemporal Dementia and various forms of Multiple Sclerosis, including primary progressive and secondary progressive variants. Studies are evaluating novel therapeutic approaches and long-term treatment options.

  • Frontotemporal Dementia Treatment
  • Multiple Sclerosis Management
  • Epilepsy Interventions

Clinical investigations include assessment of new compounds for refractory focal onset epilepsy and progressive neurological conditions.

02 Respiratory Medicine

Comprehensive studies addressing Pulmonary Fibrosis and chronic respiratory conditions. Research focuses on innovative treatments for chronic rhinosinusitis and progressive lung diseases.

  • Idiopathic Pulmonary Fibrosis
  • Chronic Rhinosinusitis
  • COPD Management

Trials aim to improve lung function and reduce disease progression in various respiratory conditions.

03 Cardiovascular Studies

Advanced research in Heart Failure and stroke prevention, particularly focusing on patients with atrial fibrillation. Studies evaluate new treatment combinations and preventive strategies.

  • Stroke Prevention
  • Heart Failure Management
  • Systemic Embolism Prevention

Research includes comparative studies of new medications for cardiac conditions and prevention strategies.

04 Oncology Research

Targeted studies on Neuroendocrine Cancers, including small cell lung cancer and other specialized cancer types. Research focuses on advanced treatment options for patients with limited therapeutic alternatives.

  • Small Cell Lung Cancer
  • Neuroendocrine Carcinoma
  • Advanced Cancer Therapies

Trials evaluate new therapeutic approaches for patients who have progressed after standard treatments.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.